Energy deficit in Huntington disease: why it matters

Fanny Mochel1,2,3,4 and Ronald G. Haller5,6

1INSERM UMR S975, Institut du Cerveau et de la Moelle, 2AP-HP, Département de Génétique, and 3Unité Fonctionnelle Neurométabolique, Hôpital La Salpêtrière, Paris, France. 4Université Pierre et Marie Curie, Paris, France. 5Department of Neurology, University of Texas Southwestern Medical Center and VA North Texas Medical Center, Dallas, Texas, USA. 6Neuromuscular Center, Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, Dallas, Texas, USA.

Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.

Introduction

Huntington disease (HD) is an autosomal dominant neurodegenerative disease with age-dependent complete penetrance. HD is caused by a CAG repeat expansion in the first exon of the HTT gene that encodes huntingtin (Htt) (1, 2). Individuals who have 36 CAG repeats or more may develop the clinical symptoms and signs of HD, including neuropsychiatric, motor, and cognitive abnormalities that cause a progressive loss of functional capacity and shortened life span. The clinical features of HD typically emerge in adulthood between 30 and 50 years of age, after which the disease progresses relentlessly over the next 15–20 years (3). Presymptomatic testing — preceded by genetic counseling according to internationally accepted guidelines — allows an at-risk person to assess their genetic status and thus predict whether a carrier will develop HD before he or she shows clinical symptoms and signs. Of importance, the presymptomatic phase in HD provides a unique window for therapeutic intervention and neuroprotection.

γ-Aminobutyric acid (GABAergic) medium spiny neurons of the striatum that contain enkephalin or substance P and project to the globus pallidus and substantia nigra are particularly vulnerable in HD and are key to the characteristic involuntary movements in this disease (4). The basis of the selective vulnerability of these neurons in HD remains elusive but may involve the reduced phosphorylation of Htt at serine 421 in the striatum (5), the specific localization of Rhes (Ras homolog enriched in striatum; a small guanine nucleotide–binding protein partner of Htt) to the striatum (6), and/or the preferential vulnerability of the striatum to mitochondrial dysfunction (7). However, the neuropathology is ultimately more widespread, affecting cortical neurons as well as the globus pallidus, substantia nigra, and brainstem. Understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability remains incomplete, but defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models (7, 8). Here we provide an overview of clinical, biochemical, and molecular evidence of an energy deficit in HD, in both the brain and the peripheral organs. We also discuss the mechanisms underlying mitochondrial and related alterations in the context of both a toxic gain-of-function from mutant Htt and the loss of function of normal Htt (Figure 1). The emerging availability of surrogate markers for clinical trials in HD, i.e., neuroimaging, neurophysiological, and neuropsychiatric changes that may be detectable as early as the presymptomatic stages of the disease (9), should open new avenues for testing promising therapeutic approaches to ameliorate the energy deficit while providing favorable safety profiles.

Normal function of Htt

Despite its identification almost two decades ago, understanding of the normal function of Htt protein is still incomplete. Although mainly found in the cytoplasm, Htt is also present in the nucleus (10, 11). Htt contains a series of up to 36 HEAT, α helix–loop–α helix, domains that mediate its interaction with numerous proteins involved in gene expression, endocytosis, vesicle trafficking, intracellular signaling, and metabolism (12–14). In particular, the role of Htt in transcription and intracellular transport is well established (15, 16). In the cytoplasm, Htt interacts with the dynein/dynactin complex and kinesin in microtubule-dependent transport of organelles in neurons, including mitochondria (17). For example, WT Htt enhances the vesicular transport of brain derived neurotrophic factor along microtubules (18). Htt may regulate transcription by shunting transcription factors between the nucleus and the cytoplasm and by interacting with spliceosome-related proteins (19). Studies in Htt knockout mice have shown that Htt is required for normal embryonic development and neurogenesis (20). Interestingly, expression of Htt is also essential for normal development in zebrafish because knock-down by antisense morpholino oligonucleotides leads to multiple developmental abnormalities, including defects in cellular iron trafficking (21), which supports previous in vitro findings that Htt may be regulated by iron levels (22). Recently, it was shown that Htt also plays a role in dividing cells through the regulation of spindle orientation during mitosis together with dynein/dynactin (23).

Pathophysiology of HD

Knockout of Htt is lethal in the mouse early in embryogenesis (24). Reduced Htt levels in knockout embryonic stem cells induce an abnormal distribution and morphology of organelles such as the endoplasmic reticulum, Golgi, and mitochondria (22). In addition, conditional Htt deletion in forebrain neurons at late embryonic or...
early neonatal stages leads to a rapidly progressive neurodegenerative phenotype (25). Reduced Htt levels have been shown to sensitize neurons to the toxic effect of mutant Htt (26). Moreover, increased expression of WT Htt in transgenic mice protected neurons from cell death (27). Similarly, increased expression of WT Htt reduced toxicity in peripheral cells overexpressing mutant Htt (28). Thus, these data indicate that a loss-of-function mechanism likely contributes to HD pathogenesis (29).

Nonetheless, cell and animal model systems as well as the direct correlation between length of CAG repeat and onset of HD strongly support the view that mutant HTT also possesses a new toxic gain of function (30). Like many neurodegenerative diseases, HD is characterized by a cascade of events leading to neuronal cell death. While the sequence of these events remains unclear, several mechanisms implicate energy defects. These include transcriptional dysregulation, changes in axonal transport, excitotoxicity, signaling dysfunction, and neuronal aggregates (31). Here we focus on the role of mitochondrial dysfunction and altered energy metabolism secondary to mechanisms such as impaired trafficking and transcriptional interference (12, 15).

Evidence of energy deficit in HD

Brain energy deficit in HD. Brain energy metabolism has been a focus of HD research for many years due to several observations in both patients and models of the disease (32). In HD patients, there is strong evidence for reduced glucose consumption in the brain, especially in the basal ganglia, even in presymptomatic mutation carriers (33–35). A brain energy deficit has also been suspected based on
The Journal of Clinical Investigation

Bioclonal evidence of energy dysfunction in HD

Mitochondrial dysfunction in HD models involves transcriptional interference and metabolic derangement in peripheral organs in order to provide energetic substrates for a chronic brain energy deficit in HD (60). The slower rate of ATP hydrolysis in striatal cells (74) and the accumulation of lipofuscin, a product of unsaturated fatty acid peroxidation, that is most prominent in vulnerable striatal neurons (81). Other markers of ROS include strand breaks in DNA (79), increased malondialdehyde (84), and the accumulation of 8-hydroxy-2′-deoxyguanosine (8dG) in HD brain and blood (82). Oxidative modification of proteins (pro) and DNA (83) is increased in HD. Dysregulation of transcriptional coactivators (PGC-1α, PGC-1γ) (45), and decreased glycolysis (46). Furthermore, experimental evidence supports the view that mitochondrial oxidative dysfunction (42), impaired mitochondrial calcium handling (43), oxidative stress (44), and ATP depletion were directly demonstrated in HD brain (47). Studies utilizing 31P-nuclear magnetic resonance (31P-NMR) showed disproportionate to decreases in the levels of calbindin, a marker of excitable cell type with high metabolic demand, shows energetic deficiency in the setting of impaired energy capacity (47).

Energy deficit in HD: not only in the brain

The existence of a peripheral mechanism is necessary to compensate for the decreased body weight (60). Instead, there is evidence for an early increase in accumulation of lipofuscin, a product of unsaturated fatty acid peroxidation, that is most prominent in vulnerable striatal neurons (81). Other markers of ROS include strand breaks in DNA (79), increased malondialdehyde (84), and the accumulation of 8-hydroxy-2′-deoxyguanosine (8dG) in HD brain and blood (82). Oxidative modification of proteins (pro) and DNA (83) is increased in HD. Dysregulation of transcriptional coactivators (PGC-1α, PGC-1γ) (45), and decreased glycolysis (46). Furthermore, experimental evidence supports the view that mitochondrial oxidative dysfunction (42), impaired mitochondrial calcium handling (43), oxidative stress (44), and ATP depletion were directly demonstrated in HD brain (47). Studies utilizing 31P-nuclear magnetic resonance (31P-NMR) showed disproportionate to decreases in the levels of calbindin, a marker of excitable cell type with high metabolic demand, shows energetic deficiency in the setting of impaired energy capacity (47).

Biochemical evidence of energy dysfunction in HD

Mitochondrial dysfunction in HD models involves transcriptional interference and metabolic derangement in peripheral organs in order to provide energetic substrates for a chronic brain energy deficit in HD (60). The slower rate of ATP hydrolysis in striatal cells (74) and the accumulation of lipofuscin, a product of unsaturated fatty acid peroxidation, that is most prominent in vulnerable striatal neurons (81). Other markers of ROS include strand breaks in DNA (79), increased malondialdehyde (84), and the accumulation of 8-hydroxy-2′-deoxyguanosine (8dG) in HD brain and blood (82). Oxidative modification of proteins (pro) and DNA (83) is increased in HD. Dysregulation of transcriptional coactivators (PGC-1α, PGC-1γ) (45), and decreased glycolysis (46). Furthermore, experimental evidence supports the view that mitochondrial oxidative dysfunction (42), impaired mitochondrial calcium handling (43), oxidative stress (44), and ATP depletion were directly demonstrated in HD brain (47). Studies utilizing 31P-nuclear magnetic resonance (31P-NMR) showed disproportionate to decreases in the levels of calbindin, a marker of excitable cell type with high metabolic demand, shows energetic deficiency in the setting of impaired energy capacity (47).

Biochemical evidence of energy dysfunction in HD

Mitochondrial dysfunction in HD models involves transcriptional interference and metabolic derangement in peripheral organs in order to provide energetic substrates for a chronic brain energy deficit in HD (60). The slower rate of ATP hydrolysis in striatal cells (74) and the accumulation of lipofuscin, a product of unsaturated fatty acid peroxidation, that is most prominent in vulnerable striatal neurons (81). Other markers of ROS include strand breaks in DNA (79), increased malondialdehyde (84), and the accumulation of 8-hydroxy-2′-deoxyguanosine (8dG) in HD brain and blood (82). Oxidative modification of proteins (pro) and DNA (83) is increased in HD. Dysregulation of transcriptional coactivators (PGC-1α, PGC-1γ) (45), and decreased glycolysis (46). Furthermore, experimental evidence supports the view that mitochondrial oxidative dysfunction (42), impaired mitochondrial calcium handling (43), oxidative stress (44), and ATP depletion were directly demonstrated in HD brain (47). Studies utilizing 31P-nuclear magnetic resonance (31P-NMR) showed disproportionate to decreases in the levels of calbindin, a marker of excitable cell type with high metabolic demand, shows energetic deficiency in the setting of impaired energy capacity (47).
increased ROS in HD and HD models has not been identified conclusively, the main suspects are mitochondria, where it is estimated that 2 percent of electron flow in the respiratory chain escapes as superoxide, predominantly via complexes I and III. Respiratory chain defects increase ROS production, and complex II inhibition models of HD display evidence of oxidative stress (87).

Among the most vulnerable targets of oxidative stress is mitochondrial aconitate. Aconitate contains an iron-sulfur cluster that is readily inactivated due to superoxide-mediated loss of iron at its catalytic site (88). In addition, the iron-sulfur cluster makes this protein highly susceptible to oxidative modification and ultimate degradation (89).

In keeping with other evidence of increased oxidative stress in HD is the finding of a profound (more than 90%) decrease in aconitate activity in HD caudate, with lesser decreases in putamen (~70%) and cortex (~50%) (42). Decreased striatal aconitate with normal levels in cortex has also been found in the R6/2 transgenic mouse model (90). α-Ketoglutarate dehydrogenase (KGDH) has also been implicated as a target of oxidative stress, though data for altered activity of this enzyme in HD is meager (91). Aconitate, KGDH, and SDH are enzymes of the TCA cycle. Defects in these enzymes in HD as well as the susceptibility of medium spiny neurons to SDH inhibition by 3-NP and malonate suggest that these neurons are particularly vulnerable to TCA cycle inhibition and that known and suspected targets of oxidative stress may restrict mitochondrial energy production in these cells by impairing TCA cycle function.

**Cellular mechanisms of altered bioenergetics in HD**

*Impaired mitochondrial calcium handling.* Mitochondria avidly accumulate calcium and play an important role in buffering changing cytoplasmic calcium levels in response to neuronal activity (92). Mitochondrial calcium transport is powered by the mitochondrial proton gradient, and increased neuronal calcium modulates mitochondrial ATP production by uncoupling oxidative phosphorylation. Calcium overload may result in discharge of the mitochondrial membrane potential, opening of the mitochondrial permeability transition (MPT) pore, release of cytochrome c, and activation of cell death pathways (92). Increased calcium influx through NMDA receptors, increased mitochondrial susceptibility to calcium transients, or both may contribute to neuronal degeneration in HD. Mitochondria isolated from lymphoblasts of HD patients and the brains of transgenic mice have a reduced membrane potential and depolarize at lower calcium concentrations than control mitochondria (93). Immunocytochemical identification of N-terminal mutant Htt on neuronal mitochondrial membranes from transgenic mice and reproduction of the mitochondrial calcium defect by incubation of normal human lymphoblast mitochondria with a fusion protein containing a long polyglutamine repeat suggest that the mitochondrial calcium defect is a direct effect of mutant Htt on mitochondria (93). The reduced mitochondrial ATP levels and decreased ATP/ADP ratio found in mutant Htt-containing striatal cells is linked to increased calcium influx through NMDA receptors, and cell ATP/ADP ratio is normalized by blocking calcium influx (49). Choo et al. (94) identified binding of both WT and mutant Htt to the outer mitochondrial membrane in mitochondria from human neuroblastoma cells and from cultured striatal cells from WT and transgenic mice. They demonstrated increased sensitivity to calcium-induced opening of the MPT and release of cytochrome c in normal liver mitochondria incubated with mutant but not WT Htt, consistent with a direct effect of mutant Htt upon mitochondrial calcium handling (94).

A possible link between impaired intracellular transport and energy deficit. There are several possible ways in which altered intracellular transport might affect energy metabolism in HD. Full-length mutant Htt may impair mitochondrial motility in mammalian neurons through both a toxic gain of function from the polyglutamine tract and a loss of function of WT Htt (95). Altered mitochondrial trafficking precedes mitochondrial and neuronal abnormalities in both in vitro and in vivo murine models of HD (95). Although aggregates were suspected to impede mitochondrial trafficking (96), N-terminal fragments of mutant Htt alone were later shown to interfere with the association of microtubule-based transport proteins with mitochondria in vitro (97). Mutant Htt altered the distribution and reduced the transport rate of mitochondria together with lowered ATP levels in the synaptosomal fraction isolated from knockin mouse brain (97). However, the mechanisms by which mutant Htt affects intracellular organelle trafficking such as mitochondria are not fully understood (44). A recent study of HD brains identified a reduced number and altered distribution of mitochondria within vulnerable, calbindin-positive striatal neurons that was more pronounced with disease progression (98).

Reductions were seen preferentially in large- and medium-size mitochondria in conjunction with an increase in levels of Drp1 protein, a mediator of mitochondrial fission and, with disease progression, a decrease in levels of Mfn1, a mediator of mitochondrial fusion (98). These results support the view that altered mitochondrial dynamics represent an important mechanism of mitochondrial dysfunction contributing to the mismatch between energy supply and demand that is a recurring theme in HD and HD models.

**Transcriptional deregulation contributes to altered bioenergetics.** Several lines of evidence suggest that transcriptional dysregulation underlies the toxicity of mutant Htt. Whether it is mediated by aggregates, soluble fractions of Htt, or by Htt itself, many transcription factors have been shown to be downregulated in HD. These include CREB-binding protein, TATA-binding protein, and Sp1/TAFII130 (99). Mutant Htt binds the tumor suppression gene p53 more avidly than does WT Htt and has been reported to increase p53 protein levels, nuclear localization, and transcriptional activity in neuronal cultures and transgenic mice (100). Augmented p53 activity was shown to mediate mitochondrial membrane depolarization and a decrease in complex IV activity, as indicated by the fact that p53 inhibition or genetic deletion ameliorated these changes in a cell culture model (100). A specific effect of mutant Htt upon p53 activity is suggested by the fact that p53 activity was not altered by another polyQ-containing protein, ataxin-1 (100). Mutant Htt has also been shown to directly decrease the expression of PGC-1α in the striatum of HD mice and patients through CREB-dependent transcriptional inhibition (45). PGC-1α is a transcriptional coactivator that regulates key energetic metabolic pathways in both brain and peripheral tissues (101). The possible role of PGC-1α in HD pathogenesis was initially suspected from the observation of selective striatal lesions in the PGC-1α knockout mouse (102). Downregulation of PGC-1α in HD striatum was then shown to affect mitochondrial energy metabolism, possibly by impairing oxidative phosphorylation (45). Conversely, HD striatal neurons expressing exogenous PGC-1α were resistant to 3-NP treatment (103). Decreasing levels of PGC-1α were shown to parallel markers of mitochondrial dysfunction with disease progression in HD brains (98). The PPARγ agonist rosiglitazone has been shown to increase mitochondrial mass in the striatal cell model of HD and to prevent the decrease in mitochondrial membrane potential and the increase in oxidative stress that otherwise occurs when these cells are challenged with pathogenic increases in intracellular calcium levels.
Therapeutic approaches targeting the energy deficit in HD

As in other neurodegenerative disorders, proven disease-modifying drugs are not yet available in HD, and most therapeutic approaches to improving energetics have aimed at providing substrates designed to slow progression or otherwise compensate for the energy deficit in HD. One such therapy is creatine, which encompasses several potential neuroprotective effects such as buffering intracellular energy pools and stabilizing intracellular calcium concentrations (109). The identification of decreased creatine levels in brain tissues from R6/2 mice (110) encouraged several trials of creatine supplementation in HD mouse models (110–113) despite a lack of overt benefit in HD patients so far (114, 115). Instead, more recent studies in which in vivo concentrations of brain metabolites were preserved by using high-resolution 1H-NMRS (116) or enzymatic microwave fixation (40) found increased brain levels of creatine and phosphocreatine in the same mouse model of HD. Moreover, clinical trials of antioxidants designed to slow the progression of the disease have been disappointing. One large-scale study assessing the potential neuroprotective effects of coenzyme Q10, a potent antioxidant and promoter of respiratory chain function, demonstrated a trend toward slowing the decline of the total functional capacity score over 30 months (117) but did not achieve statistical significance. Trials with higher doses are currently ongoing. Other antioxidant approaches were initiated in preclinical models (118, 119) but have not translated into clinical trials. Based on the hypothesis that there is a deficit of substrates for the TCA cycle in HD (60), a short-term therapeutic clinical trial was performed using an anaplerotic compound, triheptanoin, a triglyceride containing seven carbon fatty acids that is metabolized to acetyl-CoA and propionyl-CoA (a precursor of the TCA cycle intermediate, succinate). This study displayed encouraging results for the peripheral metabolism in HD patients, and in particular oxidative phosphorylation in skeletal muscle (120). However, the benefit of anaplerotic approaches for brain energy metabolism remains to be established.

The identification of PGC-1α as a key component of HD pathophysiology supports the use of therapies targeting mitochondrial biogenesis. Activation of the SIRT1 gene family by the polyphenol resveratrol potently induces mitochondrial activity through activating PGC-1α, as evidenced by increased oxidative-type muscle fibers, enhanced resistance to muscle fatigue, and increased tolerance to cold, all PGC-1α-dependent effects (121). Likewise, resveratrol was shown to partially suppress the deleterious effects of mutant polyglutamine in nematode, mouse, and mouse neuronal culture models (122, 123) and significantly reversed 3-NP–induced motor and cognitive impairment (124). In addition, treatments interfering with transcriptional deregulation, such as histone deacetylase inhibitors, were shown to improve mitochondrial dysfunction in striatal neurons from HD mice through the regulation of calcium homeostasis (125). Overall, the multiple functions of Htt in cell metabolism argue for combined therapeutic approaches in order to significantly alter the course of HD and improve energy metabolism, including restoring the normal function of Htt in intracellular transport.

Concluding remarks

Energy deficit is a prominent feature of HD. Energy deficit contributes to the progression of the disease in the brain and can also be traced to the periphery, as reflected in weight loss in HD patients. Importantly, the onset of energy-related manifestations at the presymptomatic stages of the disease, i.e., alterations in brain and muscle metabolism as well as weight loss, underscores the fact that energy deficit is likely to be an early phenomenon in the cascade of events leading to HD pathogenesis. Studies of energy metabolism in HD are therefore worth pursuing to identify potential biomarkers as well as therapeutic targets.

Although the data are not entirely concordant, biochemical studies support the view that mitochondrial dysfunction — impaired oxidative phosphorylation, TCA cycle dysfunction, and oxidative stress — is an important determinant of altered energy metabolism in HD. Impaired bioenergetics in HD likely represent downstream effects of both a mutant Htt toxic gain-of-function and a loss-of-function of the WT protein, which, nonetheless, may extend beyond mitochondrial dysfunction. Better understanding of the bioenergetics in HD will more fully illuminate the role of impaired intracellular transport and transcriptional dysregulation in the disease. While treatments designed to improve energy metabolism in the brain and peripheral organs of patients and presymptomatic individuals may not reverse the primary defect in HD on their own, they are likely to significantly alter the course of the disease, delaying disease onset and the pace of disease progression.

Acknowledgments

The authors are grateful to Alexandra Dürr, Sandrine Humbert, and Frédéric Saudou for fruitful discussions.

Address correspondence to: Ronald G. Haller, Department of Neurology, VA Medical Center and University of Texas Southwestern Medical Center and Neuromuscular Center, Institute for Exercise and Environmental Medicine of Presbyterian Hospital, Dallas, Texas 75231, USA. Phone: 214.345.4617; Fax: 214.345.4618; E-mail: Ronald.Haller@UTSouthwestern.edu.
review series

lishing; 2008:1585–1586.
88. Gardner PR, Rainier I, L. B. E., White CRW. Superoxide radical and iron modulate aconitase activity in mamma-
90. Tabrizi SJ, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgen-
92. Trushina E, et al. Mutant huntingtin impairs axo-
93. Van Foreest P, et al. Defects in adaptive energy metabolism and mitochondrial calcium function and dysfunc-
96. Kimura H, et al. Shiga's tunnel: possible role of proline oxoglutarate dehydrogenase: a target and generator of oxi-
98. Browne SE, et al. Oxidative damage and metab-
olic dysfunction in Huntington’s disease: selective vulnerabil-
100. Fukui H, Moraes CT. Extended polyglutamine repeats trigger a feedback loop involving the mito-
chondrial complex I, the proteasome and huntingtin-
105. Lin J, et al. Layer-dependent susceptibility of mitochondria to the calcium-
106. Lee ST, et al. Slowed progression in models of Hun-
108. Santamaria A, et al. Comparative analysis of super-
109. Deleuze V, et al. Mitochondrial calcium function and dysfunc-
110. Andreasen OA, et al. Creatine increase survival and delays motor symptoms in a transgenic ani-
111. Ferrante RJ, et al. Neuroprotective effects of creat-
112. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neu-
113. Schalling M, et al. Resveratrol protects against perox-
115. Lajkovic M, et al. Resveratrol improves mitochon-
116. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment ameliorates the Hunting-
117. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neu-
118. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment ameliorates the Hunting-
119. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neu-
120. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment ameliorates the Hunting-
121. Parker JA, et al. Resveratrol rescues mutant poly-
glutamine cytoxicity in nematode and mamma-
122. Ho DJ, Calingasan NY, Wilke E, Dumont M, Beal MF. Resveratrol protects against peripheral defi-
123. Kumar P, Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced bio-
chemical changes in peripheral nerve: possible neu-
124. Oliveira JM, et al. Mitochondrial-dependent CA2+

review series

The Journal of Clinical Investigation http://www.jci.org Volume 121 Number 2 February 2011 499